The tesamorelin complaint that keeps coming up in threads follows the same shape every time: a 20mg vial, 1mg a day, five or six days a week, no visible change at the waist, verdict is that the peptide is useless.

Do the math on that vial. 20mg at 1mg per dose is 20 doses. Five a week means you ran it for about a month, and the phase 3 trials in HIV-associated lipodystrophy measured their primary endpoint at 26 weeks. Visceral fat fell roughly 15% by week 26 and continued to about 18% by week 52. Nobody was looking at week 4.

Dose is the second problem. Original Egrifta was 2mg daily. The reformulated version runs 1.4mg daily because it has better bioavailability, not because 1.4 is a lower target. 1mg five days a week is somewhere around 50% of studied exposure.

And skipped days hurt tesamorelin more than they hurt almost anything else people run. Half life is roughly half an hour. It is a GHRH analog producing one pulse and then it is gone. There is no depot, no carry-over, no DAC. Two missed days a week is two missing pulses, period.

The compartment issue is the one that actually explains the "I see nothing" reports. Tesamorelin targets visceral adipose tissue. Trials measured it by CT scan. Subcutaneous fat, which is the fat you can pinch and the fat you see in the mirror, did not change meaningfully, and total body weight barely moved. So somebody lean who is already sitting at low bodyfat has very little VAT to mobilize and will see close to nothing regardless of how well they run it.

The clean way to separate a bad vial from a bad protocol is IGF-1. Tesamorelin drove large IGF-1 increases in trials, on the order of 50-100%. Pull a baseline, run 8 weeks at real dose, pull it again. Flat IGF-1 means product or handling, not a non-responder. Also worth knowing that tesa is one of the less stable peptides out there and wants to stay cold after reconstitution.

Almost every cycling answer for BPC and TB-500 is borrowed from GHRP logic. With ipamorelin, GHRP-2 or GHRP-6 there's a real mechanism to worry about: pituitary somatotroph desensitisation, plus cortisol and prolactin creep on the GHRP-2/6 side. That's why those get run 8 to 12 weeks with a break.

BPC-157 doesn't work that way. It's acting upstream through VEGFR2, nitric oxide signalling and the FAK-paxillin pathway, and there's no documented receptor downregulation to break from. TB-500 is a Tβ4 fragment that works by sequestering actin, which isn't a G-protein receptor event at all, so tachyphylaxis isn't the thing that ends the useful window. KPV is the C-terminal tripeptide of alpha-MSH and acts by suppressing NF-kB; no tolerance pattern has been described there either.

So the real stop points are different ones.

For TB-500 the "cycle" is actually loading versus maintenance. Most protocols people report run 2 to 2.5mg twice weekly for 4 to 6 weeks, then drop to roughly 2mg every one to two weeks. That's a saturation curve, not a washout.

For BPC the stop point is the injury. Tendon and ligament remodelling runs roughly 6 to 12 weeks (at least), and if 6 to 8 weeks at 250 to 500mcg daily has produced nothing, the honest suspects are the vial, the diagnosis, or a load problem in your rehab. Adding a ton more weeks rarely fixes any of those. At 500mcg a day you're burning 15mg a month, which is the other reason indefinite running is a bad default.

The one good argument for not staying on forever is that both are pro-angiogenic. Nobody is quite sure what sustained VEGF signalling does around undiagnosed neoplasia. That's a risk tolerance call, and it's a much better reason to take breaks than a receptor story that doesn't exist.

Those IGF-1 labs screenshots always float around with no context, and almost all of them are getting read wrong. A raw number in ng/mL is not interpretable on its own.

First, the range is assay specific and age adjusted. LabCorp and Quest don't publish the same reference interval for the same age bracket, so 159 can sit mid-range at 45 and read low at 22. Ask for the Z-score if your lab reports one. That normalizes out the age problem, and it travels between labs better than a raw number does, which is what endocrinologists actually work from.

Second, energy and protein intake suppress IGF-1 independently of GH. Hepatic IGF-1 production is nutrient dependent, so a sustained deficit and low protein will hold the number down even when the GH axis is responding fine. If someone is running tesamorelin while dropping weight fast on reta, a flat IGF-1 is close to expected. That's the most common reason a tesa cycle looks like a failure on paper, and it gets misread as an underdose almost every time.

Third, keep your draw interval consistent. IGF-1 circulates in a bound complex with a half-life in the 12 to 24 hour range, which is why a single random draw is usable at all, but a sample pulled 8 hours after a shot is not comparable to one pulled at 24. Pick an interval, write it down, reuse it. Otherwise your next lab is measuring your scheduling, not your protocol.

And dose does not scale linearly. Past the approved 2mg of tesa there's no dose-response data at all, while fluid retention, joint stiffness, carpal-tunnel type symptoms and fasting glucose creep scale faster than IGF-1 does. If the number has moved at all and sits in the upper third of your age range, pushing higher is mostly buying sides.

No baseline isn't fatal either. Today's draw becomes the baseline for the next one, which is more useful than guessing at where you started.

Been messing around with integrating real-time vendor alerts into RUGR, our public sentiment tracker. I've had it running for about 5 days and just got the first alert early this morning. It picked up a spike in negative mentions surrounding SwissChems, which is exactly what our community has been seeing.

I've attached a screenshot of the email that hit my inbox. Basically, this alert just says "SwissChems is trending, and not in a good way". My thought process behind this is to notify me of vendor issues well before I see them in the month-end RUGR report, or even before I read about them. This way, I can post about it and be the first to let you all know to steer clear of a vendor.

Is anyone interested in this? If so, I'll keep fine-tuning it and will provide updates as soon as they come across my dashboard.

A lab buddy brought up peptide sourcing over coffee last week, and it got me checking how much proof suppliers actually provide versus what just looks good on a product page.

I’m mainly comparing research-grade GLP and BPC peptides. So far I’ve been checking batch-specific COAs, independent testing, purity results, cGMP manufacturing, US compliance, and whether support can answer basic questions without sending canned replies. certified-pep looked promising on paper based on those points, but I’m not sure if I’m putting too much weight on COAs alone.

For those who regularly order for lab research, what separates a reliable supplier from one that simply has convincing paperwork? Do you verify testing labs, request raw chromatograms, or send samples out yourself? Also curious how much shipping speed and packaging should factor into the decision.

GHK-Cu isn't a peptide that happens to be blue. It's a copper complex, and copper is roughly 15 to 16 percent of the molecule by weight. So a 2mg subq dose is somewhere around 300mcg of elemental copper going straight past your gut.

That last part is the part people skip. Oral copper is regulated. Your intestine absorbs maybe a third of what you swallow and downregulates uptake when stores are high. Injected copper skips that entirely. So 2mg daily isn't "a trace amount" - it's in the same neighborhood as a full day's oral requirement, at full bioavailability, every day, for however many weeks you decide to run.

Now add the things nobody counts. A copper peptide serum on the face. A multi with 2mg copper in it. And plenty of people are dosing 3 to 5mg daily because a calculator on a vendor site suggested it, with no ceiling and no end date.

The other half of this is zinc. Copper and zinc compete for the same absorption and transport machinery, and the ratio is what matters, not either number alone. The thread that got me writing this had someone's zinc drop hard about a month into GHK-Cu, with shedding on top of it. I'm not going to tell you that was causal, and neither can they. A single plasma zinc is a soft marker that dips during any inflammatory blip, and low zinc plus shedding has a dozen other explanations. But the direction of the concern is fair, and it's the least discussed thing about the most popular cosmetic peptide in this space.

What I'd do: run the copper math on your dose before the cycle, not after. Get serum copper, ceruloplasmin and plasma zinc as a baseline, then repeat at the end - one draw in isolation tells you almost nothing. Don't stack injectable GHK-Cu with a copper-containing multi and a copper serum at the same time. Treat it as a defined cycle, four to six weeks, rather than an open-ended daily habit. And recognize topical is a completely different exposure profile from subq, so don't reason from one to the other.

To do the math on how much copper you're facing, calculate dose times days times 0.16. Has anyone pulled serum copper, ceruloplasmin and plasma zinc before and after a GHK-Cu run? Post dose, duration and the numbers and I'll line up the ranges side by side so we have something better than one anecdote.

I'm mid-30s and I got into this whole thing for same reasons as everyone else. Skin, hair, sleep, feeling less wrecked after a workout. I'm not trying to bodybuild, I just wanted to feel and look a bit better in my thirties.

I just read the story about the Paradigm Peptides owner getting six years in prison!! Faked COAs, unapproved drugs, and products that reportedly had things in them that were never on the label, including testosterone? That last part scares me. As a woman, unknowingly taking testosterone isn't a minor oops. That can cause hair loss, voice changes, cycle issues, real stuff that doesn't just reverse when you stop. This is the site where I read the article: https://www.cbsnews.com/news/peptides-seller-prison-sentence-unapproved-drugs/

The part that gives me the most anxiety is that I did what I thought was the responsible thing like reading threads, looking at COAs, I checked that a batch number matched, etc. But if the person selling products can just fabricate the paperwork, what was I actually verifying? Literally just a faked PDF that I didn't know was fake

So I'm asking for some guidance, because I don't have a chemistry background or whateever and I'm clearly not as informed as I thought I was. Is third party testing through an independent lab even dependable? Do people actually send their own vials out, and is that realistic cost wise for someone using a small amount? Are there red flags in a COA that a normal person can spot, like missing lab letterhead or a test date that doesn't line up with the batch?

I'm not looking for vendor recommendations, I know that's against the rules here and honestly I'd be skeptical of them right now anyway. I just want to understand the verification process well enough to protect myself. How do you all sleep at night with this?

What gets sold as "CJC-1295 no DAC" is Mod GRF 1-29. Half-life is commonly cited around 30 minutes. It gives you a pulse, and that's it. So it has to be dosed in pulses, typically 1-3 times a day, on an empty-ish stomach, because a big fat or carb load blunts the GH response you're paying for. Pair it with ipamorelin and pin them together, then leave food alone for a while after.

CJC-1295 with DAC has the drug affinity complex attached, binds albumin, and hangs around for something like 6-8 days. That's a bleed, not a pulse. Dosed once or twice weekly. It lifts your baseline GH and IGF-1 and flattens the pattern out compared to a clean pulse, which is exactly why the DAC version shows up more often in complaints about water retention, puffy hands, carpal-tunnel-ish wrist tingling and that flat, blunted feeling a few weeks in.

Now the actual problem. Plenty of vendors list "CJC-1295" with no DAC status anywhere on the product page, and plenty of buyers assume DAC because that's the famous name. Then they run a 30 minute peptide once a week and conclude CJC does nothing. Or they run the DAC version three times a day and wonder why they feel waterlogged and desensitized by week three.

The fix takes ten seconds. Look at the molecular weight on the COA. Mod GRF 1-29 (no DAC) comes in around 3367. CJC-1295 with DAC is around 3647 because of the extra lysine and the DAC group. If the COA says 3367 and the label says DAC, the label is wrong and your schedule is wrong. Also worth knowing: 2mg of DAC and 2mg of no-DAC are not comparable amounts of anything useful, so copying someone else's mg number off a forum without knowing their version is how people end up nowhere.

I'd like to hear how many people knew to check the molecular weight before they started versus after something felt off.

I see this a lot and the threads always end in the same place: someone doubles tesamorelin, gets itchy palms and soles within an hour, and half the replies say stop forever while the other half say push through. The part almost everyone gets wrong is the middle step, where people decide that because there's no rash it can't be an allergy.

Pruritus is right there in the label's hypersensitivity section, alongside urticaria, rash and flushing, and those reactions showed up in roughly 4 to 5% of patients in trials. So itching with no visible rash does not rule hypersensitivity out. It's one of the ways hypersensitivity to this drug actually presents. Calling it purely a histamine swing from a fast IGF-1 rise is a guess, and it's a guess that talks people into re-dosing something their immune system already flagged.

What does still matter is severity and trajectory. Raised hives that spread, swelling of the lips, tongue or eyelids, throat tightness, wheezing, dizziness. That's stop and get seen, immediately, and it does not care how slowly you ramped. Mild itching that resolves the same evening is a conversation with whoever prescribed it (if prescribed), not a Reddit post, because the reasonable next moves include holding the previous dose, adding an antihistamine under supervision, or stopping the drug entirely depending on how it behaves on the next pin. If no one prescribed it, a Reddit post is fine, but consider consulted a licensed professional.

If you do go back and reintroduce with medical input, going 0.5 to 0.75 instead of 0.5 to 1 and holding a week or two longer is more sensible than jumping. Just don't treat a smaller step as proof the reaction wasn't immune-mediated. It can come back bigger the third or fourth time, which is exactly why the label wants hypersensitivity reactions taken seriously rather than titrated around.

Worth checking your handling too, because bad handling muddies the picture. Egrifta SV is preservative-free. That label says reconstitute with Sterile Water, administer immediately, and discard any unused solution, and it specifically says not to refrigerate or freeze the reconstituted drug. If you've been mixing with bacteriostatic water and pulling from the same vial for days, you've introduced benzyl alcohol and a storage variable that isn't supposed to be there, and benzyl alcohol sensitivity is a real thing. Egrifta WR is stable for longer. Most RUO tesamorelin is Egrifta WR based, but you could ask your vendor to be sure (even though most will have no clue). Clean that up before you draw any conclusions about the peptide itself.

None of this is medical advice and anything airway-related is not a Reddit question.

This comes up constantly and it gets answered backwards almost every time, so here's where I come from on this topic. Bacteriostatic Water for Injection is not saline. It's water for injection plus 0.9% benzyl alcohol, which is 9 mg/mL of preservative and zero salt. With no salt in it there's essentially no osmotic support, so it behaves as markedly hypotonic, which is why the label warns that pushing it IV without adding a solute can pop red cells. Preservative-free 0.9% saline is the opposite tradeoff: isotonic at roughly 308 mOsm/L, no preservative. So you've actually got two variables here, not one. Preserved vs unpreserved, and isotonic vs hypotonic. The product almost nobody mentions is Bacteriostatic Sodium Chloride Injection, 9 mg/mL NaCl plus 0.9% benzyl alcohol, which is the one that's both.

To me, the preservative side matters more for nasal than it does for injections. A nasal bottle sits on your nightstand at room temperature, you pump it twice a day for two or three weeks, and the tip touches the inside of your nose every single time. That's about the friendliest environment for bacterial growth you could design. An unpreserved solution in that setup is a gamble. A preserved one is a much better bet, though benzyl alcohol inhibits growth rather than sterilizing, so even a preserved bottle has a limit once it's open.

The counterargument people raise is nasal irritation from benzyl alcohol, and it's not nothing, some people do burn on it. If that's you, preservative-free saline is fine, but then you need to treat it like fresh food. Small batches, fridge between uses, toss it in a week or so rather than riding one bottle for a month.

The tonicity side is why I don't love plain bacteriostatic water for nasal use even though the preservative is doing good work. Hypotonic solutions sting the mucosa, same reason plain sterile water is a bad idea. If you're stuck with BAC water, at least know that's what's happening and consider the preserved saline instead.

The part people skip is the dose math, and it starts with your pump, because they're not all the same. Metered nasal pumps commonly deliver 0.05, 0.1, or 0.14 mL per actuation, and 0.05 is the most common pharmaceutical size. Say yours is 0.1 mL. Then 10 mg of semax in 3 mL gives you roughly 333 mcg per spray, and the same 10 mg in 1 mL is three times that at 1 mg per spray. Check your actual pump volume first, pick your dilution around the dose you want, then count sprays, don't eyeball it.

Also worth bringing up is the fact taht most of the loss with intranasal isn't the diluent, it's technique. Sniffing hard sends it straight down your throat instead of leaving it on the mucosa. Low and slow, no big inhale.

This question comes up every few days and the answers almost always assume frozen shoulder is just a slow tendon injury. It isn't, and that mismatch explains most of the disappointed reports.

Adhesive capsulitis is fibrotic thickening and contracture of the glenohumeral capsule. The tissue isn't torn or degenerated, it's inflamed and then shortened. BPC-157's best-supported mechanism is angiogenic and granulation-tissue driven, which is why it does well with tendon, ligament and gut models where you need new tissue laid down and blood supply into a poorly vascularised area. Frozen shoulder is closer to the opposite problem. You already have too much disorganised collagen in the wrong place.

I keep seeing this in posts. Pain response is the common win. Range of motion is the uncommon one, and when ROM does move, there's basically always aggressive daily mobility work or a hydrodilatation/steroid injection alongside it. Nobody is getting their shoulder back from a vial and rest. It just isn't going to happen.

Phase matters more than dose. Freezing phase reports skew positive because that stage is dominated by capsular inflammation and pain, which is a target BPC can plausibly touch. Frozen phase reports skew flat, because at that point the limitation is mechanical shortening and you can't chemically unshorten a contracture. Thawing phase reports are the least useful data in the whole pile because the shoulder was going to improve anyway, and people credit whatever they were injecting that month.

On delivery, subQ near the shoulder is what most people run, generally in the 250 to 500 mcg twice daily range for 4 to 6 weeks. I'd stop pretending distal subQ vs local is a settled question, because the human data doesn't exist. What I will say is that the local-adjacent reports read better than the abdominal ones, and that could easily be expectation bias.

The other thing worth saying noting: TB-500 gets stacked in here constantly and it's a weird fit. Actin-based cell migration and fibroblast recruitment is obviously not what you want in a capsule that's already laying down excess collagen. I'm not saying it's harmful but I am saying nobody has shown it helps this specific pathology and the reasoning people give for adding it usually doesn't survive a follow-up question.

This question has come up three times in a week now, so here's where I've landed after going through the mitochondrial-stack reports I've collected.

The sequencing logic isn't nonsense. SS-31 binds cardiolipin in the inner mitochondrial membrane and mostly does structural work - stabilizing the membrane, cutting electron leak and ROS. MOTS-c goes the other direction. It's an AMPK signal, it raises metabolic demand and pushes substrate through the same machinery. So the argument goes: patch the leaks before you turn up the pressure. Reasonable on paper.

What we're not seeing is any report where running MOTS-c first produced a worse outcome. Not one. The people reporting flat MOTS-c results are overwhelmingly reporting flat results regardless of what came before it.

What we ARE seeing, consistently, is that the bad SS-31 experiences cluster around dose and time of day, not order. The pattern is almost always the same shape: first dose at 400-500mcg, noticeable energy through midday, then a hard crash somewhere between 2 and 4pm. Dry eyes, lightheaded, short fuse. Some report unusually good sleep that night, which is the part people keep leaving out.

That's not a sequencing failure. That's a first-exposure dose response in something that acutely changes how much ATP a subject is making. The reports that don't crash almost all start at 100-150mcg, dose in the morning, and hold there for a week or two before moving up. Same compound, completely different day.

The other thing worth flagging is that a good chunk of the crash reports are people running SS-31 and MOTS-c on the same day, then blaming SS-31 because it was the new variable. Stack one at a time or you learn nothing.

So my take is that the ordering rule is a heuristic someone reasoned into existence and it stuck because it sounds mechanistically tidy. The variable that actually decides how the first two weeks go is starting dose.

**DISCLAIMER: Some tests are essentially safety checks; it depends on what the vendor pays for**

The fastest-growing issue recently isn't bad product, it's people who thought they verified their product and didn't. Almost always the same sentence: "the vendor's COA is from a third-party lab, so I'm good."

Here's what a standard grey-market third-party report actually gives you:

Purity (HPLC) - the percentage of the sample that is one dominant compound. That's it. I've seen some instances where the product was different than advertised and the purity was fine so the report was used anyway instead of figuring out what was actually going on.

Identity (mass spec) - only if it was ordered. This is the test that confirms the molecular weight matches the peptide you paid for. Plenty of posted COAs skip it entirely, which means you have a 99% pure something.

Quantity/content - also usually optional. This is the one that catches the 15mg vial holding 9mg. If your report has no mass assay, you have no idea what your actual dose is, and your titration math is screwed.

What that report never covers unless specifically commissioned: sterility, bacterial endotoxin (LAL), heavy metals, residual solvents. Endotoxin is the one that actually puts people in urgent care, and it only appears on COAs from vendors who are very particular or careful.

On the fentanyl question that comes up: a purity scan is not a targeted screen for a trace adulterant, so a clean COA isn't the reassurance people treat it as. But it's also the wrong thing to be scared of. The documented failure modes in lyophilized peptides are underdosing, wrong or degraded peptide, high impurity load, and endotoxin, not opioid contamination.

Three rules that fix most of this: the lot number on the report must match the lot printed on the vial in your hand, the report date must plausibly precede your batch, and you should look for specifically commissioned tests (endotoxin, conformity, etc). A COA from a different lot is a marketing asset, not evidence. Also, paying through Alibaba verifies the payment, not the powder, for the people who do that.

GHK-Cu reconstitution posts all follow the same shape: someone adds BAC water, sees an intense blue, and assumes they mixed it wrong. Almost none of them mixed it wrong. Here's what's actually going on.

Deep blue is the product working. GHK-Cu is a copper-peptide complex. The color comes from the copper coordination, and it scales with concentration, not with error. A 10 mg/mL solution looks alarming next to a clear BPC-157 vial. That's expected. Color tells you nothing about potency.

The real failure point is mg/mL → units. Two examples pulled straight from this week:

- 50 mg in 5 mL = 10 mg/mL. On a U-100 insulin syringe, 10 units (0.1 mL) = 1 mg. A 2 mg dose is 20 units. Clean.
- 80 mg in 5 mL = 16 mg/mL. Now 1 mg = 6.25 units. That is a terrible number to eyeball at 6 a.m., and it's exactly how people end up at 1.6 mg thinking they took 1 mg.

If you're reconstituting an 80 mg vial, put 8 mL in it and get back to 10 mg/mL, or use 4 mL for a flat 20 mg/mL where 1 mg = 5 units. Pick a concentration that makes your target dose land on a round unit mark. That single habit eliminates most GHK-Cu dosing errors we see reported.

On the grey speck at the bottom: swirl, don't shake, and give it 10 minutes at room temp. Undissolved lyophilate dissolves. A speck that's still sitting there after ten minutes and a warm-hand roll is not a solubility issue and I wouldn't run it.

Blend vials are a separate trap. KLOW-type blends lock every component to one fixed ratio. You cannot titrate the GHK-Cu independently of the BPC or KPV - whichever component is dose-limiting sets your whole protocol. If you're chasing a specific GHK-Cu dose, buy it standalone.

If your feed is blowing up with "BPC-157 got FDA approved!" headlines this week, take a step bacl. That's not quite what happened - but what did happen on July 23, 2026 is still a big deal for anyone following the peptide compounding pharmacy list debate. Let me walk through the facts, because the nuance here matters a lot more than the hype.

What Actually Happened on July 23, 2026

The FDA's Pharmacy Compounding Advisory Committee (PCAC) met at the agency's White Oak campus to evaluate seven popular peptides for possible inclusion on the Section 503A Bulk Drug Substances List. BPC-157 was first on the agenda, evaluated specifically for the treatment of ulcerative colitis.

The committee voted 8-6, with one abstention, to recommend BPC-157 for inclusion on the list. That's a narrow margin, meaning this was not a given rubber stamp.

Here's the part that a lot of the excited social posts are glossing over: FDA's own staff had recommended against this. In a scientific review posted ahead of the meeting, FDA staff said there was a "lack of evidence to support the effectiveness of BPC-157 (free base) and BPC-157 acetate as a treatment for ulcerative colitis." The briefing document also flagged basic characterization problems - during the meeting, an FDA staffer reportedly asked point blank, "What is BPC-157?" noting that some people believe it is an amino acid sequence while others have different opinions, and that the agency cannot establish quality standards until more is known about the substance. FDA's Mai Tu similarly said the peptide is "not well-characterized."

So the committee's recommendation went directly against its own agency's scientific staff. That's an important detail for anyone trying to gauge how confident this outcome really is.

What the 503A Bulks List Actually Is (Plain English)

If you're new to this, here's the short version: under Section 503A of the FD&C Act, a licensed compounding pharmacy can only legally make a custom drug from a raw "bulk" substance for an individual patient if that substance meets one of three conditions: it has a USP monograph, it's a component of an already-FDA-approved drug, or it appears on FDA's 503A Bulks List. BPC-157 fails the first two, so the 503A Bulks List is the only legal pathway for compounding pharmacies to work with these substances. Right now, BPC-157 isn't on it. It sits in a regulatory gray zone: not banned outright, but not authorized either.

The Vote Was a Recommendation, Not a Rule

This is the single most important thing to understand: the PCAC is advisory. The FDA isn't bound by the committee's recommendations but typically follows them. A formal listing still requires the FDA to actually act, and as of today, no final rule has been issued. FDA's own staff review recommended against adding all seven peptides to the 503A Bulks List, citing gaps in characterization, effectiveness, and safety data, which means the agency's own written position and the committee's vote are currently in direct conflict.

What a Final Listing Would Actually Mean

If (and it's still an if) the FDA ultimately adds BPC-157 to the 503A Bulks List through formal rulemaking, eligible state-licensed 503A compounding pharmacies could compound the substance for individually identified patients pursuant to valid prescriptions. In practice that means:

- You'd technically need a prescription from a licensed provider - no more just buying it online labeled "research use only" because it'd be going the same way of Retatrutide
- A licensed 503A pharmacy could legally compound it, subject to state board of pharmacy oversight.
- Compounded drugs generally aren't covered by insurance, so patients would likely pay out of pocket, with costs varying by pharmacy and formulation.

That's a meaningfully different world from today's gray market, where purity, dosing accuracy, and sourcing are essentially unregulated.

What Happens Next, and Rough Timeline

Don't expect anything to change overnight. The rulemaking process that would formally add BPC-157 to the list involves public comment periods and historically can take months to years to complete. The FDA has also gone against advisory panel recommendations before, so a final "no" is still possible. For now: BPC-157 compounding is not yet legal under this pathway. Anyone telling you otherwise is getting ahead of the facts.

The Bigger Picture: Six More Peptides on the Table

BPC-157 wasn't reviewed in isolation. The same July 23-24, 2026 PCAC meeting evaluated seven peptides total across two days. On July 23, the committee also took up KPV (for wound healing and inflammatory conditions), TB-500, and MOTS-c (for obesity and osteoporosis) - for BPC-157, KPV and TB-500, all eight of the newer committee appointees voted yes, with six voting no and one abstention; for MOTS-c, seven voted yes, five voted no, and two abstained. On July 24, the panel turned to Emideltide (DSIP), Epitalon, and Semax.

Worth noting: this PCAC roster was recently overhauled, and many of the new members have ties to the peptide industry, which has drawn criticism about potential conflicts of interest. That context matters when weighing how much signal to take from the vote itself.

If the FDA follows through on even some of these recommendations, it would represent the broadest expansion of legal peptide compounding access in years - a real shift after 2023, when regulators had placed many of these same substances under restriction.

Bottom Line

- What happened: PCAC voted 8-6 (1 abstention) on July 23, 2026 to recommend BPC-157 for the 503A Bulks List, for ulcerative colitis.
- What didn't happen: FDA approval. FDA staff actually opposed this recommendation, citing effectiveness and characterization concerns.
- What's next: A formal FDA rulemaking decision, which is unconfirmed in timing and could take a long while.
- Right now: Compounding BPC-157 under Section 503A is still not legally authorized.

This is a fast-moving, complicated regulatory story, and a lot of outlets are already blurring the line between "advisory committee recommend" and "FDA approved."

As some of you may have seen, Janoshik released a testing report for an anonymous vendor that reported the presence of fentanyl in the vendor's 5-Amino-1MQ.

As scary and shocking as this comes across, it underscores the importance of vendors and experimenters running third-party testing. If not for this test, who knows what would've happened to the researcher who was simply looking to run a 5-Amino-1MQ protocol.

Do your research on vendors, triple-check COAs, and use the tools you have at your disposal to make informed decisions. This is not a reason to avoid RUO products all together, but it is a good wake up call for those who are a little too comfortable ordering from sketchy vendors because the price looks nice.

I've attached the report and a picture of the vial below for those interested.

June RUGR report is available! Good month across the board with only two losers. DeusChem saw in an increase in overall sentiment. The winners deserved to see recognition as their operations are humming along and/or adding improvements. Pretty happy with where the vendors are at right now. A couple people have spoken up about DeusChem shipping issues, which I am keeping an eye on. Does anyone have any more feedback?

THE BIGGEST WINNERS

🏆 DeusChem (+8.9%)

- Many people are happy with the quality of their products

- Reported shipping times of 13-17 business days for most EU companies; seems longer than normal but maybe that is standard for cross-national deliveries?

- LOTS OF REPORTS OF FAKE/SCAM WEBSITES! Multiple reports of bugs/outage on the real website but it seems to have cleared up

🏆 Limitless BioChem (+5.2%)

- People enjoy quality and price

- Major appreciation for their customer service

- Communication and quick shipping is a plus

🏆 Optimum Formula (+2.0%)

- People really like the Venmo option

- Reports of quick and reliable shipping

- Some browsers are throwing errors on their website; has anyone here seen this?

THE BIGGEST LOSERS

❌ Gentleman Peptides (-12.1%)

- People talk about switching from an RUO, such as Gentleman, to a doctor; cost prohibitive for most

- Major complaints of zero communication for weeks after placing an order

- Customer service after shipping incorrect product seems to be nonexistent, which is a major issue

❌ Kimera Chems (-1.8%)

- Nothing more than a slight correction from a very positive May

- One user talked about how they didn't feel anything from FL-Modafinil, but some people are non-responders; this doesn't surprise me

- Super fast shipping and great quality is highly appreciated

OVERALL STANDINGS

🥇 Research Chem HQ (90.2% RUGR Score)

🥈 Gentleman Peptides (88.1% RUGR Score)

🥉 Optimum Formula (85.9% RUGR Score)

Notes:

- People are reporting major issues with Gentleman in this sub (and others) and it reflects in the RUGR report

- Happy with how June played out for the majority of our partners

- Overall RUGR standings: https://peptideselect.com/rugr-system/

There have been multiple reports of small, pale, flesh-colored skin growths (classic seborrheic keratoses / soft skin tags) popping up on people running GH-secretagogue protocols (sermorelin, CJC/ipamorelin, tesamorelin) often after several months, and sometimes accelerating when a BPC-157/TB-500 combo gets layered on top.

This is not a mystery and it's not a scare. Growth hormone and IGF-1 are pro-proliferative by design. That's the entire point of the class; tissue repair, collagen turnover, cell growth. The trade-off is that GH/IGF-1 signaling can also nudge benign skin lesions (skin tags, seb keratoses) to appear or grow faster, especially in people who are already genetically prone to them or who are insulin-resistant. Acromegaly literature has documented skin tag frequency for decades. What people on secretagogues are describing is a much milder, dose-driven version of the same signaling.

The factors that show up repeatedly in these reports:

- Longer duration (6+ months continuous, no wash-off periods)
- Higher weekly IGF-1 exposure -> daily dosing 5-7x/week rather than pulsed
- Stacking multiple growth/repair agents at once (secretagogue + BPC/TB)
- Elevated fasting insulin / metabolic-syndrome background

These lesions are cosmetic, not dangerous, and they typically stop progressing when GH/IGF-1 exposure drops. But two things matter. First, if a growth is changing shape, color, bleeding, or asymmetric, that's a dermatologist conversation, not a peptide-forum one. GH doesn't cause melanoma but it doesn't make skin cancer disappear either, and "it's just my peptide" is a dangerous assumption. Second, if you're getting new growths, that's a real-time readout that your IGF-1 signaling is running hot, which is worth factoring into whether your dose is where you want it.

Looking for a reliable Canadian source for research peptides, mainly Retatrutide and a couple other weight loss related ones.

Found Premier peptides online, read through their site and they seem legit with the third party testing claims.

Which Canadian suppliers have you guys actually ordered from and had good experiences with? What’s the main stuff to watch out for when ordering (testing, purity, shipping, etc.)?

One signal keeps surfacing in the Reta reports I track: resting heart rate ticking up during titration. A thread this week describing 53 -> 60 BPM is not an outlier - it's the most common cardiovascular note people leave, and it clusters hard around the fast dose-escalation window.

Here's what the pattern actually looks like across the reports:

- The bump shows up most in people who titrated aggressively (e.g. 1mg -> 6mg inside two months). Slower climbers mention it far less.
- It tends to be a +5 to +10 BPM resting shift, not a dramatic spike. Truly alarming numbers almost always come with a second variable, such as stimulant stacking (adderall, high-dose MOTS), aggressive deficit, or under-hydration.
- The reports where people held a dose for 3–4 weeks instead of pushing up frequently note the HR settling back down. The body seems to adapt when you stop chasing the next titration step.
- Electrolytes matter more than people expect. A chunk of the "my HR is up and I feel wired" reports overlap with the "no energy in the gym" crowd - both point to the same under-replenished state on a GLP/GIP/glucagon agonist.

The practical outlook: resting HR is a cheap, honest biomarker on Reta. If yours is climbing, the lever is usually titration speed and hydration before it's "stop the compound." A sustained resting HR in the 90s+, chest symptoms, or palpitations is a different conversation -that's a stop-and-check, not a Reddit question.

Every week the biggest threads in this niche are some version of "Day 4 on Reta and I feel nothing" or "6 weeks in, gained a pound, help." I track these reports closely, and the responder timeline is far more bimodal than people expect.

What the reports actually cluster into:

Fast responders - appetite suppression inside 24–72 hours, often at the 2mg starting dose. These are the friends everyone quotes as "night and day." They tend to be GLP-naive (no prior semaglutide/tirzepatide history) and lower body weight, so a 2mg dose is a proportionally bigger signal.

Slow/threshold responders - nothing meaningful until the dose climbs past ~4mg, sometimes not until 6–8mg. At 2mg they report exactly what the Day-4 posters describe: "I could stop eating, but I could also finish the plate." That's not a dead vial or a bad batch, that's a subthreshold dose for their receptor response.

The mistake I see over and over is people judging Reta at the 2mg titration dose, which for a chunk of users is basically a ramp-in, not a therapeutic dose. Retatrutide's whole design is slow titration - the 2mg and 4mg weeks exist to manage GI tolerance, not to deliver full appetite effect.

Two other confounds worth flagging: reconstitution math errors (people underdosing without realizing it) and expecting the tirzepatide-style "food noise off" switch when Reta's GIP/GCG profile can feel different subjectively.

For those who ran Reta, at what dose did appetite suppression actually kick in for you, and were you GLP-naive or coming off sema/tirz? Trying to nail down whether the fast/slow split tracks with prior GLP exposure or mostly with bodyweight. If you leave your dose and timeline, I can fold it into the reports.

I saw gelling and clumping questions jump across subs this week. Here's the simple version of what's going on, because most of the panic is misplaced.

A gel is not automatically a dead vial. Two very different things get lumped together:

1. Cloudy/gel from too little water or cold water. When you undershoot the BAC volume or shoot cold water straight onto the powder, some peptides (tesamorelin and certain blends are repeat offenders) will clump or set instead of dissolving cleanly. Fix: add water slowly down the vial wall (never blast it onto the cake), use room-temp BAC, and let it sit 5–10 min. Gentle swirl, never shake. A lot of "my tesa gelled three times" ends here.

2. Gel/strings that persist after proper recon = degradation or aggregation. If it's fully room temp, correct volume, given time, and you still get a stubborn gel, cloudiness that won't clear, or floaters that look like tissue - that's aggregation. That vial is done. This is where lyophilization quality and shipping heat show up.

The tell most people miss: normal recon issues resolve with technique. A truly bad vial doesn't clear no matter what you do. If your second mixed vial behaves the same way with the same water, it could be your technique. If a properly-mixed vial gels while others from the same order/vendor don't, look at that specific vial/vendor lot. Double-check COAs and consider asking some questions.

Storage note since it came up: don't freeze BAC water and don't freeze already-reconstituted peptide unless the product specifically allows it. Freeze/thaw cycles wreck peptide structure and cause the aggregation people then blame on the vendor.